Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by

Newcastle AuthorsTitleYearFull text
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
Dr Stephen Hobson
et al.
An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)2021
Professor Nilanjan Chakraborty
Effects of the cold wall boundary on the flame structure and flame speed in premixed turbulent combustion2021
Svitlana Korolchuk
Professor Jane Endicott
Professor Martin Noble
Dr Mathew Martin
Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition2019
Stephanie Myers
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
Dr Tim Blackburn
et al.
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Professor Bernard Golding
Dr Ian Hardcastle
et al.
Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines2017
Dr Christopher Wong
Dr Ian Hardcastle
Emeritus Professor Herbie Newell
Dr Mangaleswaran Sivaprakasam
Huw Thomas
et al.
Structure-guided design of purine-based probes for selective Nek2 inhibition2017
Dr Gary Beale
Dr Emma Haagensen
Huw Thomas
Charlotte Revill
Professor Bernard Golding
et al.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
Emeritus Professor Herbie Newell
Professor Steve Wedge
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation2016
Dr Allyson Campbell
Dr Celine Cano
Professor Jane Endicott
Professor Bernard Golding
Dr Karen Haggerty
et al.
8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode2014
Professor Bernard Golding
Dr Celine Cano
Professor Jane Endicott
Professor Martin Noble
Emeritus Professor Herbie Newell
et al.
Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors2014
12345